Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that Health Canada has granted a Notice of ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio ...

Biocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...

Yesintek is ustekinumab injection and Yesintek I.V. is ustekinumab for injection, solution for intravenous infusion. These ...

Alternative pharmacy benefit manager Serve You Rx is seeking to generate additional savings for its clients by adding two biosimilars for the popular drug Stelara to its formulary. The PBM will add ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...